{
    "clinical_study": {
        "@rank": "3353", 
        "arm_group": [
            {
                "arm_group_label": "Walking meditation & Walking", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Walking meditation & No exercise", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Walking Meditation  training would yield more favorable adaptations than walking alone in\n      improving glycemic control and vascular function in patients with type 2 diabetes."
        }, 
        "brief_title": "The Effect of Walking Meditation Training on Glycemic Control and Vascular Function in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The inclusion criteria included type 2 diabetes (as defined by the American Diabetes\n             Association), a baseline glycosylated hemoglobin (HbA1c) value of 7-9%, and no\n             previous exercise training in the past 6 months. All participants were free from\n             diabetic nephropathy, diabetic retinopathy, severe diabetic neurophathy, severe\n             cardiovascular and cerebrovascular diseases.\n\n        Exclusion Criteria:\n\n          -  Participants were excluded if they dropped out or completed less than 80% of the\n             training schedule."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123901", 
            "org_study_id": "SPSC-1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Walking meditation & Walking", 
                    "Walking meditation & No exercise"
                ], 
                "description": "Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced \"Budd\" and \"Dha\" with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.", 
                "intervention_name": "Walking Meditation", 
                "intervention_type": "Other", 
                "other_name": "Buddhist Walking Meditation"
            }, 
            {
                "arm_group_label": "Walking meditation & Walking", 
                "description": "Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.", 
                "intervention_name": "Walking", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Walking meditation & No exercise", 
                "description": "Sedentary life style.", 
                "intervention_name": "No exercise", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mind and body Exercise", 
            "Flow mediated dilation", 
            "Diabetes"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "link": {
            "url": "http://www.diabetes.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Kasorn Seangyee, M.sc.", 
                "phone": "6680-258-1403"
            }, 
            "facility": {
                "address": {
                    "city": "Prapadang", 
                    "country": "Thailand", 
                    "state": "Samut Prakan", 
                    "zip": "10130"
                }, 
                "name": "The Primary Health Promoting Hospital"
            }, 
            "investigator": {
                "last_name": "Daroonwan Suksom, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "THE EFFECT OF WALKING MEDITATION TRAINING ON GLYCEMIC CONTROL AND VASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES", 
        "overall_official": {
            "affiliation": "Faculty of Sports Science, Chulalongkorn University", 
            "last_name": "Daroonwan Suksom, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Thailand: Ethical Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The glycemic control will be quantified using blood samples. Fasting blood glucose, HbA1c, and insulin  will be measured with standard procedures at the clinical laboratory (Bria Lab, Bangkok, Thailand).Homeostasis model assessment (HOMA), the parameter for insulin resistance, will be calculated by using equation of [Fasting glucose (mg/dL) \u00d7 Insulin level (uU/mL) / 405].", 
                "measure": "Change from baseline in glycemic control", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Vascular reactivity or brachial artery flow-mediated dilatation (FMD) will be assessed with the ultrasound equipment (CX50, Philips, USA), using the blood occlusion technique on the right forearm. The brachial artery will be imaged above the antecubital fossa in the longitudinal plane. Baseline data will be  monitored and the cuff placed around the right forearm will be inflated to 50 mmHg above systolic blood pressure for 5 minutes and then deflated for 5 minutes of recovery. FMD will be  calculated from the formula FMD=(D2-D1)x100/D1 when D1 is the brachial artery diameter at baseline, D2 is the maximal post-occlusion brachial artery diameter", 
                "measure": "Change from baseline in vascular reactivity", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123901"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chulalongkorn University", 
            "investigator_full_name": "Assoc. Prof. Dr.Daroonwan Suksom", 
            "investigator_title": "Faculty of Sports Science", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma cortisol will be measured with standard procedures at the certified clinical laboratory (BRIA Lab, Bangkok, Thailand).\nHeart rate variability (HRV) will be measured using the Heart rate variability analyzer SA-3000P, Medicore Co.,Ltd, Korea", 
                "measure": "Change from baseline in stress indicators", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Body composition will be measured using Body Composition Analyzer (Model ioi 353, Jawon Medical Co. Ltd., Korea).\nMaximal oxygen consumption (VO2max) will be assessed by Modified Bruce Protocol for treadmill test with Stationary Gas Analyzer (Vmax\u2122 Encore 29 system, Yorba Linda, CA).\nLower muscle strength will be measured with back and leg dynamometer.", 
                "measure": "Change from baseline in physical fitness", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Pulse wave velocity measurement will be assessed with MD6 bidirectional transcutaneous Doppler probe (Hokanson, Bellevue, WA, USA). All subjects were monitored with an EKG and PWV measurements in the computer and used as timing markers for PWV identification.", 
                "measure": "Change from baseline in Peripheral arterial stiffness", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Ankle-brachial index will be evaluated with a manual MD6 bidirectional transcutaneous Doppler probe (Hokanson, Bellevue, WA, USA) and will be calculated by dividing the highest ankle systolic blood pressure by the highest brachial systolic blood pressure.", 
                "measure": "Change from baseline in ankle-brachial index.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "description": "Interleukin-6 (IL-6) will be measured in plasma samples with the ELISA kit (Human IL-6 high sensitivity ELISA, eBioscience, Austria).\nNitric oxide (NO) will be measured in plasma samples with the commercial assay kit (Colorimetric nitric oxide assay kit, PromoKine, Germany).", 
                "measure": "Change from baseline in blood chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 12"
            }
        ], 
        "source": "Chulalongkorn University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chulalongkorn University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}